Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01VVL
|
|||
| Former ID |
DNC001568
|
|||
| Drug Name |
PF-04523655
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 2 | [1] | |
| Therapeutic Class |
siRNA
|
|||
| Company |
Pfizer; Quark Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HIF-1 responsive protein RTP801 (DDIT4) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01445899) PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME). U.S. National Institutes of Health. | |||
| REF 2 | Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.